TC
BMRN icon

TwinBeech Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

TwinBeech Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341K Buy
+5,966
New +$327K 0.06% 270
2025
Q3 		– Sell
-299,229
Closed -$16.4M – 581
2025
Q2 		$16.4M Buy
+299,229
New +$17.6M 0.37% 80
2024
Q4 		– Sell
-320,287
Closed -$22.5M – 632
2024
Q3 		$22.5M Buy
+320,287
New +$26.8M 0.43% 60
2023
Q1 		– Sell
-100,053
Closed -$10.4M – 625
2022
Q4 		$10.4M Sell
100,053
-61,870
-38% -$5.81M 0.2% 146
2022
Q3 		$13.7M Buy
+161,923
New +$14.4M 0.36% 88
2021
Q2 		– Sell
-15,874
Closed -$1.2M – 455
2021
Q1 		$1.2M Buy
15,874
+8,900
+128% +$727K 0.18% 171
2020
Q4 		$612K Buy
+6,974
New +$553K 0.1% 259

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

TwinBeech Capital's BMRN Position: Q2 2026 in Review

TwinBeech Capital opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 5,966 shares worth $341K. The stake represents 0.06% of the portfolio and ranks #270 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in BMRN as recently as Q2 2025.

TwinBeech Capital first reported a position in BMRN in Q4 2020 and has held it in 7 quarters since. The position peaked at $22.5M in Q3 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • TwinBeech Capital held 5,966 shares of BioMarin Pharmaceuticals worth $341K as of Q2 2026.
  • BioMarin Pharmaceuticals was a new TwinBeech Capital position in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.06% of TwinBeech Capital's portfolio in Q2 2026, its #270 holding.
  • TwinBeech Capital first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 7 quarters since.
  • TwinBeech Capital's BioMarin Pharmaceuticals position peaked at $22.5M in Q3 2024.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.